This invention describes a novel compound with prominent commercial value as a therapeutic treatment for neural conditions such as, autism, epilepsy, and schizophrenia. These disorders have been linked to inhibitory synapse defects formed by interneurons in the hippocampal region of the brain. Researchers at Virginia Tech have synthesized peptides to regulate the formation and function of inhibitory brain synapses, allowing neural defects to be corrected with the use of this innovative compound. To date, animal studies have been completed and have shown promising efficacy potential.